Rob Dillard

DocwireNews

This month, the US Food and Drug Administration (FDA) <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-endometrial-cancer-indication-dostarlimab-gxly-chemotherapy" target="_blank" rel="noopener">approved</a> dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer (EC). Dostarlimab-gxly was previously approved with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent EC that is mismatch repair deficient or microsatellite instability-high.Treatment efficacy was assessed in RUBY, a randomized, multicenter, double-blind, placebo-controlled trial comprising 494 patients with primary advanced or recurrent EC. Patients in the population of interest were randomized 1:1 to either dostarlimab-gxly with carboplatin and paclitaxel, followed by dostarlimab-gxly, or placebo with carboplatin and paclitaxel, followed by placebo.The major efficacy end point measures were progression-free survival (PFS) and overall survival (OS). According to the results, in the overall population, researchers observed a statistically significant OS improvement, with a median OS of 44.6 months (95% CI, 32.6 to not reached) and 28.2 months (95% CI, 22.1-35.6) in the dostarlimab-gxly and placebo arms, respectively (hazard ratio [HR], 0.69 [95% CI, 0.54-0.89]; 1-sided P=.002). The median PFS in the overall population was 11.8 months (95% CI, 9.6-17.1) and 7.9 months (95% CI, 7.6-9.5) in the dostarlimab-gxly and placebo arms, respectively (HR, 0.64 [95% CI, 0.51-0.80]; 1-sided P&lt;.0001).The recommended dostarlimab-gxly dose is 500 mg every 3 weeks for 6 cycles with carboplatin and paclitaxel, followed by 1000-mg monotherapy every 6 weeks until disease progression or unacceptable toxicity, or up to 3 years. Some of the most common adverse reactions (&ge;20%) with dostarlimab-gxly with carboplatin and paclitaxel include anemia, increased creatinine, peripheral neuropathy, decreased white blood cell count, fatigue, nausea, alopecia, low platelets, increased glucose, lymphopenia, neutropenia, liver function test abnormalities, arthralgia, rash, constipation, diarrhea, decreased albumin, abdominal pain, and dyspnea.&nbsp;

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

FDA Expands Approval of Treatment Combination for Endometrial Cancer

Gynecologic Cancer

The FDA approved dostarlimab-gxly with carboplatin and paclitaxel for endometrial cancer.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe